Imugene

Imugene Market capitalization

The The market capitalization of Imugene (IMU.AX) as of Nov 19, 2026 is 81.99 M AUD. In the previous year, The market capitalization was 81.99 M AUD — a change of 0.00% (lower).

Market capitalization

81.99 MAUD

YoY

0.00%

Last updated:

In 2026, Imugene's market cap stood at 81.99 M AUD, a 0.00% increase from the 81.99 M AUD market cap in the previous year.

The Imugene Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2019
81.99 M AUD
Jan 1, 2020
81.99 M AUD
Jan 1, 2021
81.99 M AUD
Jan 1, 2022
81.99 M AUD
Jan 1, 2023
81.99 M AUD
Jan 1, 2024
81.99 M AUD
Jan 1, 2025
81.99 M AUD
Jan 1, 2026
81.99 M AUD
The Imugene Market capitalization history
YEARMarket capitalizationYoY
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD0.00%
81.99 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imugene Stock analysis

What does Imugene do? Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Imugene's Market Capitalization

Imugene's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Imugene's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Imugene's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Imugene’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Imugene stock

The market capitalization of Imugene is 81.99 M AUD in 2026.

The market capitalization of Imugene changed from 81.99 M AUD to 81.99 M AUD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Imugene since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Imugene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imugene

All Key Metrics — Imugene